AGENUS INC 8-K

What Happened

• On July 13, 2026, Agenus Inc. (AGEN) entered a Securities Purchase Agreement for a private placement expected to close on July 15, 2026. The deal will issue 23,035,227 common shares (or pre-funded warrants exercisable at $0.01), Series A warrants to buy 21,144,277 shares (exercise $4.02) and Series B warrants to buy 33,797,214 shares (exercise $5.03).
• The combined effective purchase price per Share (including attached Series A and B warrants) is $3.69 (less the $0.01 pre-funded exercise price, if used), for expected gross proceeds of ~$85 million at closing and up to an additional ~$255 million if all warrants are exercised. The Company also executed a Registration Rights Agreement to register resale of the issued securities.

Key Details

• Expected closing: July 15, 2026 (subject to customary conditions).
• Securities: 23,035,227 Shares (or pre-funded warrants), Series A warrants for 21,144,277 shares, Series B warrants for 33,797,214 shares.
• Exercise prices: Pre-funded warrants $0.01; Series A $4.02; Series B $5.03. Combined effective price per unit: $3.69.
• Board changes: Company will increase its board to nine directors and, following a designation notice by Commodore Capital Master LP, appoint two Commodore‑designated directors to newly created Class III seats.
• Use of proceeds restrictions: Net proceeds cannot be used for business development, equity repurchases, or early repayment/defeasance of debt.
• Cash runway guidance: With existing cash plus net proceeds, Agenus expects funding into Q3 2027 (assuming no warrant exercises) and potentially through year-end 2031 (assuming full exercise of warrants).
• Warrant mechanics: Warrants include exercisability limits (beneficial ownership caps of 4.99%/9.99% with optional increase to 19.99% with notice), exercise windows tied to clinical milestones, and protections on “fundamental transactions” (cash-out purchase rights based on Black‑Scholes value).

Why It Matters

• Financing and dilution: The transaction provides immediate cash (~$85M) to fund operations and advance the pipeline but creates potential future dilution if warrants are exercised (up to ~+$255M of additional capital and substantial incremental share issuance).
• Governance: Appointment of two directors designated by Commodore Capital gives that investor influence on the board while the Company commits to maintaining those designees while Commodore owns ≥5%.
• Strategic shift: Agenus explicitly prioritizes botensilimab + balstilimab (BOT+BAL) for neoadjuvant treatment of MSS colon cancer and plans a registrational Phase 3 (ROBBIN) — first patient dosing anticipated Q1 2027, interim pathologic response data H2 2027, interim EFS analysis H2 2029, final EFS H2 2030 — and will discontinue financial support for the BATTMAN late‑line metastatic MSS CRC study.
• Liquidity for investors: The Registration Rights Agreement requires the company to file a resale registration statement (file within 45 days of closing; use best efforts to be effective within 90 days), which facilitates secondary market sales of the issued securities once effective.